Concizumab

Names

[ Name ]:
Concizumab

Biological Activity

[Description]:

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia[1][2].

[Related Catalog]:

Research Areas >> Others

Signaling Pathways >> Others >> Others

[Target]

TFPI[1][2].

[In Vitro]

Concizumab 以浓度依赖性方式增加凝血酶峰值[1]。

[In Vivo]

Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用[2]。 Animal Model: Cynomolgus monkeys (target mediated drug disposition (TMDD) model)[2]. Dosage: 20mg/kg or 200 mg/kg Administration: Intravenous injection/subcutaneous injection Result: Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.

[References]

[1]. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696.

[2]. Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.